Preclinical data suggest that concurrent treatment of anti‐CD38 and anti‐PD‐1/PD‐L1 antibodies can substantially reduce primary tumor growth by reversing T‐cell exhaustion, and thus may synergize with anti‐PD‐1/PD‐L1 treatment. The gene discussed is PDCD1; the disease is neoplasm.